From a sequence on paper to a lyophilized powder in a vial: the six steps, where impurities come from, and an honest answer about origin.
Nearly every research peptide you will encounter is built this way.
A peptide is a chain of amino acids in a defined order. Manufacturing starts from that sequence, which determines every step that follows, including which protecting groups are needed and where the difficult couplings will be.
Most research peptides are built by solid-phase peptide synthesis, the method Bruce Merrifield won the 1984 Nobel Prize in Chemistry for. The chain is anchored to an insoluble resin bead and extended one amino acid at a time. Because the growing chain stays attached to the resin, excess reagents and byproducts can be washed away after every cycle rather than requiring purification at each step.
Each cycle removes a protecting group from the end of the chain, then couples the next amino acid. Fmoc chemistry is the common modern approach. Every cycle is an opportunity for a small percentage of chains to fail to react, which is the origin of most impurities in the finished material.
When the sequence is complete, the peptide is cleaved from the resin and the side-chain protecting groups are removed, usually with a strong acid such as TFA. The crude product at this stage contains the target peptide along with truncated and deletion sequences from failed couplings.
The crude material is separated by preparative high-performance liquid chromatography, which is what converts a crude mixture into a high-purity product. This step largely determines whether the finished material is 95% or 99% pure, and it is also the most expensive step, which is why it is the one most often cut short.
The purified peptide is analyzed, typically by HPLC for purity and mass spectrometry for identity, then freeze-dried into the stable white powder that arrives in the vial. The analytical results from this stage are what should appear on the Certificate of Analysis.
This question gets asked constantly, and most of the answers online are marketing. Here is the version we will stand behind.
China manufactures a very large share of the world's peptide raw material, including material that ends up in Western pharmaceutical supply chains. Some of the largest and most technically capable peptide facilities in the world are Chinese. Treating "made in China" as automatically inferior is not accurate, and any vendor telling you otherwise is selling you a story rather than a fact.
It is equally true that poor-quality material ships from everywhere, including from US-based sellers who are reselling imported powder they never tested. Origin alone does not tell you what is in the vial.
There are real, practical differences, and they are about supply chain rather than chemistry. A shorter chain of custody means fewer handling and temperature variables between synthesis and your door. Domestic testing is easier to verify, because you can contact the laboratory. And if a batch is not what was represented, recourse against a domestic company is considerably more straightforward than against an overseas one.
Purification depth and the analysis proving it. The gap between 95% and 99% purity is mostly how thoroughly preparative HPLC removed the failed sequences, and that step costs money, which is precisely why it is the one that gets cut. The only way to know which you received is a lot-specific Certificate of Analysis from a laboratory with no stake in the answer.
The large majority of research peptides are produced by solid-phase peptide synthesis. The peptide chain is anchored to a resin bead and assembled one amino acid at a time through repeated deprotection and coupling cycles, then cleaved from the resin, purified by preparative HPLC, analyzed for purity and identity, and freeze-dried into a lyophilized powder. Longer peptides and proteins are more often produced by recombinant expression in bacterial or yeast systems instead.
Not inherently, and claiming otherwise would be inaccurate. China manufactures a very large share of the world's peptide raw material, including material used by Western pharmaceutical companies, and some of the largest and most capable peptide facilities in the world operate there. Poor material also ships from every country, including the United States. Country of origin is a weaker quality signal than the documentation attached to a specific batch: who tested it, by what method, and against what specification.
Practical reasons rather than chemical ones. Shorter supply chains mean fewer handling and temperature variables between synthesis and delivery. Domestic testing is easier to verify and follow up on, and recourse is more straightforward if a batch is not what was represented. Those are supply-chain and accountability advantages, not a claim that the underlying chemistry is superior.
The purification step and the analytical verification behind it. Every synthesis produces some truncated and deletion sequences; the difference between 95% and 99% purity is largely how thoroughly those were removed by preparative HPLC. What tells you which one you have is a lot-specific Certificate of Analysis from an independent laboratory showing the method, the specification and the result.
Synthetic peptides are assembled chemically, amino acid by amino acid, which suits shorter sequences and allows non-natural amino acids and modifications. Recombinant peptides and proteins are expressed by genetically engineered cells and then purified, which is generally more economical for longer chains. Most research peptides in the 5 to 40 amino acid range are made synthetically.
Ask, and ask for the batch documentation. A supplier should be able to say where material was synthesized and where it was tested, and provide a lot-specific COA naming the testing laboratory. A vendor unable or unwilling to answer either question has told you something useful regardless.
The support assistant can explain any synthesis or analytical term on this page.
How to read a COA